Revolution of Helicobacter pylori treatment.
Antibiotic resistance
Gastric cancer
Helicobacter pylori
Susceptibility-based treatment
Vaccination
Journal
Journal of gastroenterology and hepatology
ISSN: 1440-1746
Titre abrégé: J Gastroenterol Hepatol
Pays: Australia
ID NLM: 8607909
Informations de publication
Date de publication:
27 Feb 2024
27 Feb 2024
Historique:
received:
28
01
2024
accepted:
07
02
2024
medline:
28
2
2024
pubmed:
28
2
2024
entrez:
28
2
2024
Statut:
aheadofprint
Résumé
Helicobacter pylori infection is a major global health concern, and its management has witnessed a revolutionary shift with the emergence of antibiotic resistance. In this review, I explore the mechanisms of H. pylori antibiotic resistance and highlight the critical need for susceptibility-based eradication treatments. The increasing prevalence of antibiotic-resistant strains requires innovative approaches to combat this resilient pathogen. I also delve into the importance of mass screening as a preventive strategy for early detection and intervention, describing my experience in Bhutan. Additionally, I explore promising alternatives, such as vaccination. The aim of this review is to provide insight into the evolving landscape of H. pylori treatment and highlight the need for a paradigm shift in the approach to combating this persistent bacterial infection.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIH HHS
ID : DK62813
Pays : United States
Informations de copyright
© 2024 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
Références
Schistosomes, liver flukes and Helicobacter pylori. IARC Monogr. Eval. Carcinog. Risks Hum. 1994; 61: 1-241.
Uemura N, Okamoto S, Yamamoto S et al. Helicobacter pylori infection and the development of gastric cancer. N. Engl. J. Med. 2001; 345: 784-789.
Hsu P-I, Lai K-H, Hsu P-N et al. Helicobacter pylori infection and the risk of gastric malignancy. Am. College Gastroenterol.|ACG 2007; 102.
Tsuda M, Asaka M, Kato M et al. Effect on Helicobacter pylori eradication therapy against gastric cancer in Japan. Helicobacter 2017; 22.
de Kraker ME, Stewardson AJ, Harbarth S. Will 10 million people die a year due to antimicrobial resistance by 2050? PLoS Med. 2016; 13: e1002184.
Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect. Dis. 2018; 18: 318-327.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2021; 71: 209-249.
Ford AC, Yuan Y, Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer: systematic review and meta-analysis. Gut 2020; 69: 2113-2121.
Malfertheiner P, Megraud F, Rokkas T et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut 2022.
El-Serag HB, Kao JY, Kanwal F, Gilger M, LoVecchio F, Moss SF et al. Houston Consensus Conference on testing for Helicobacter pylori infection in the United States. Clin. Gastroenterol. Hepatol. 2018; 16: 992-1002.e6.
Liou JM, Malfertheiner P, Lee YC et al. Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus. Gut 2020; 69: 2093-2112.
She RC, Wilson AR, Litwin CM. Evaluation of Helicobacter pylori Immunoglobulin G (IgG), IgA, and IgM serologic testing compared to stool antigen testing. Clin. Vaccine Immunol. CVI 2009; 16: 1253-1255.
Ansari S, Yamaoka Y. Helicobacter pylori infection, its laboratory diagnosis, and antimicrobial resistance: a perspective of clinical relevance. Clin. Microbiol. Rev. 2022; 35: e0025821.
Kouhsari E, Sadeghifard N, Khadiv A et al. Heteroresistance to clarithromycin and metronidazole in patients with a Helicobacter pylori infection: a systematic review and meta-analysis. Ann. Clin. Microbiol. Antimicrob. 2022; 21: 19.
Brandi G, Biavati B, Calabrese C et al. Urease-positive bacteria other than Helicobacter pylori in human gastric juice and mucosa. Am. J. Gastroenterol. 2006; 101: 1756-1761.
Mahachai V, Vilaichone R-K, Pittayanon R, Rojborwonwitaya J, Leelakusolvong S, Maneerattanaporn M et al. Helicobacter pylori management in ASEAN: the Bangkok consensus report. J. Gastroenterol. Hepatol. 2018; 33: 37-56.
Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of Helicobacter pylori infection. Am. J. Gastroenterol. 2017; 112: 212-239.
Fallone CA, Chiba N, van Zanten SV et al. The Toronto Consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology 2016; 151: 51-69.e14.
Sugano K, Tack J, Kuipers EJ, Graham DY, El-Omar EM, Miura S et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut 2015; 64: 1353-1367.
Chen Q, Liang X, Long X, Yu L, Liu W, Lu H. Cost-effectiveness analysis of screen-and-treat strategy in asymptomatic Chinese for preventing Helicobacter pylori-associated diseases. Helicobacter 2019; 24: e12563.
Lee YC, Lin JT, Wu HM et al. Cost-effectiveness analysis between primary and secondary preventive strategies for gastric cancer. Cancer Epidemiol. Biomarkers Prev. 2007; 16: 875-885.
Graham DY, Liou JM. Primer for development of guidelines for Helicobacter pylori therapy using antimicrobial stewardship. Clin. Gastroenterol. Hepatol. 2022; 20: 973-83.e1.
Nyssen OP, Espada M, Gisbert JP. Empirical vs. susceptibility-guided treatment of Helicobacter pylori infection: a systematic review and meta-analysis. Front. Microbiol. 2022; 13: 913436.
Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E. Prevalence of antibiotic resistance in Helicobacter pylori: a systematic review and meta-analysis in World Health Organization regions. Gastroenterology 2018; 155: 1372-82.e17.
Shu X, Ye D, Hu C, Peng K, Zhao H, Li H, Jiang M. Alarming antibiotics resistance of Helicobacter pylori from children in Southeast China over 6 years. Sci. Rep. 2022; 12: 17754.
Helmbold L, Ghebremedhin B, Bellm A, Hopkins MA, Wirth S, Aydin M. Increased antibiotic resistance in children with Helicobacter pylori infection: a retrospective study. Pathogens 2022; 11: 178.
Tshibangu-Kabamba E, Yamaoka Y. Helicobacter pylori infection and antibiotic resistance-from biology to clinical implications. Nat. Rev. Gastroenterol. Hepatol. 2021; 18: 613-629.
Scaletsky IC, Aranda KR, Garcia GT, Gonçalves ME, Cardoso SR, Iriya K, Silva NP. Application of real-time PCR stool assay for Helicobacter pylori detection and clarithromycin susceptibility testing in Brazilian children. Helicobacter 2011; 16: 311-315.
Jehanne Q, Bénéjat L, Mégraud F, Bessède E, Lehours P. Evaluation of the Allplex™ H pylori and ClariR PCR assay for Helicobacter pylori detection on gastric biopsies. Helicobacter 2020; 25: e12702.
Redondo JJ, Keller PM, Zbinden R, Wagner K. A novel RT-PCR for the detection of Helicobacter pylori and identification of clarithromycin resistance mediated by mutations in the 23S rRNA gene. Diagn. Microbiol. Infect. Dis. 2018; 90: 1-6.
Hays C, Delerue T, Lamarque D et al. Molecular diagnosis of Helicobacter pylori infection in gastric biopsies:evaluation of the Amplidiag(®)H. pylori + ClariR assay. Helicobacter 2019; 24: e12560.
Bénéjat L, Ducournau A, Lehours P, Mégraud F. Real-time PCR for Helicobacter pylori diagnosis. The best tools available. Helicobacter 2018; 23: e12512.
Kakiuchi T, Okuda M, Matsuo M, Fujimoto K. Smart Gene™ as an effective non-invasive point-of-care test to detect Helicobacter pylori clarithromycin-resistant mutation. J. Gastroenterol. Hepatol. 2022; 37: 1719-1725.
Li Y, Lv T, He C et al. Evaluation of multiplex ARMS-PCR for detection of Helicobacter pylori mutations conferring resistance to clarithromycin and levofloxacin. Gut Pathogens 2020; 12: 35.
Jenks PJ. Causes of failure of eradication of Helicobacter pylori. BMJ (Clinical Research Ed) 2002; 325: 3-4.
Yan TL, Gao JG, Wang JH, Chen D, Lu C, Xu CF. Current status of Helicobacter pylori eradication and risk factors for eradication failure. World J. Gastroenterol. 2020; 26: 4846-4856.
O'Connor JP, Taneike I, O'Morain C. Improving compliance with Helicobacter pylori eradication therapy: when and how? Therap. Adv. Gastroenterol. 2009; 2: 273-279.
George LL, Borody TJ, Andrews P, Devine M, Moore-Jones D, Walton M, Brandi S. Cure of duodenal ulcer after eradication of Helicobacter pylori. Med. J. Aust. 1990; 153: 145-149.
Li Y, Choi H, Leung K, Jiang F, Graham DY, Leung WK. Global prevalence of Helicobacter pylori infection between 1980 and 2022: a systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 2023; 8: 553-564.
Zou Y, Qian X, Liu X et al. The effect of antibiotic resistance on Helicobacter pylori eradication efficacy: a systematic review and meta-analysis. Helicobacter 2020; 25: e12714.
Dore MP, Leandro G, Realdi G, Sepulveda AR, Graham DY. Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy: a meta-analytical approach. Dig. Dis. Sci. 2000; 45: 68-76.
Malfertheiner P, Bazzoli F, Delchier JC et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet 2011; 377: 905-913.
Wang G, Wilson Trevor JM, Jiang Q, Taylor DE. Spontaneous mutations that confer antibiotic resistance in Helicobacter pylori. Antimicrob. Agents Chemother. 2001; 45: 727-733.
Dascălu RI, Bolocan A, Păduaru DN et al. Multidrug resistance in Helicobacter pylori infection. Front. Microbiol. 2023; 14.
Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010; 59: 1143-1153.
Ailloud F, Didelot X, Woltemate S et al. Within-host evolution of Helicobacter pylori shaped by niche-specific adaptation, intragastric migrations and selective sweeps. Nat. Commun. 2019; 10: 2273.
Rizvanov AA, Haertlé T, Bogomolnaya L, Abadi TB, A. Helicobacter pylori and its antibiotic heteroresistance: a neglected issue in published guidelines. Front. Microbiol. 2019; 10: 1796.
Vilaichone RK, Yamaoka Y, Shiota S et al. Antibiotics resistance rate of Helicobacter pylori in Bhutan. World J. Gastroenterol. 2013; 19: 5508-5512.
Vilaichone RK, Aumpan N, Ratanachu-Ek T, Uchida T, Tshering L, Mahachai V, Yamaoka Y. Population-based study of Helicobacter pylori infection and antibiotic resistance in Bhutan. Int. J. Infectious Dis.: IJID 2020; 97: 102-107.
Matsunari O, Miftahussurur M, Shiota S et al. Rare Helicobacter pylori virulence genotypes in Bhutan. Sci. Rep. 2016; 6: 22584.
Vilaichone RK, Aumpan N, Ratanachu-Ek T, Gamnarai P, Uchida T, Tshering L et al. Efficacy of omeprazole, tetracycline, and 4 times daily dosing of amoxicillin in Helicobacter pylori eradication in limited resource area in Bhutan: a prospective randomized trial (BHUTAN Study). Asian Pac. J. Cancer Prev. 2020; 21: 1109-1114.
Kato M, Ota H, Okuda M et al. Guidelines for the management of Helicobacter pylori infection in Japan: 2016 revised edition. Helicobacter 2019; 24: e12597.
Dorji D, Dendup T, Malaty HM, Wangchuk K, Yangzom D, Richter JM. Epidemiology of Helicobacter pylori in Bhutan: the role of environment and geographic location. Helicobacter 2014; 19: 69-73.
Chophel T, Tshering S, Dorji N, Tshomo U. Stomach cancer screening services of Bhutan. Indian J. Surg. 2022; 1-6.
Shiotani A, Lu H, Dore MP, Graham DY. Treating Helicobacter pylori effectively while minimizing misuse of antibiotics. Cleve. Clin. J. Med. 2017; 84: 310-318.
D'Elios MM, Czinn SJ. Immunity, inflammation, and vaccines for Helicobacter pylori. Helicobacter 2014; 19: 19-26.
Graham DY. Determinants of antimicrobial effectiveness in H. pylori gastritis. In: Hunt RH, GNJ T, eds. Helicobacter pylori: Basic Mechanisms to Clinical Cure. Dordrecht: Springer Netherlands, 1994; 531-537.
Graham DY, Dore MP. Helicobacter pylori therapy: a paradigm shift. Expert Rev. Anti Infect. Ther. 2016; 14: 577-585.
Hori Y, Imanishi A, Matsukawa J et al. 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases. J. Pharmacol. Exp. Ther. 2010; 335: 231-238.
Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut 2016; 65: 1439-1446.
McFarland LV, Huang Y, Wang L, Malfertheiner P. Systematic review and meta-analysis: Multi-strain probiotics as adjunct therapy for Helicobacter pylori eradication and prevention of adverse events. United Eur. Gastroenterol. J. 2016; 4: 546-561.
Sutton P, Boag JM. Status of vaccine research and development for Helicobacter pylori. Vaccine 2019; 37: 7295-7299.
Bugaytsova JA, Piddubnyi A, Tkachenko I, Rakhimova L, Edlund JO, Thorell K et al. Vaccination with Helicobacter pylori attachment proteins protects against gastric cancer. bioRxiv : the preprint server for biology 2023.
Bugaytsova JA, Moonens K, Piddubnyi A, Schmidt A, Edlund JO, Lisiutin G et al. Helicobacter pylori attachment-blocking antibodies protect against duodenal ulcer disease. bioRxiv : the preprint server for biology 2023.
Shanks AM, El-Omar EM. Helicobacter pylori infection, host genetics and gastric cancer. J. Dig. Dis. 2009; 10: 157-164.
Yamaoka Y. Mechanisms of disease: Helicobacter pylori virulence factors. Nat. Rev. Gastroenterol. Hepatol. 2010; 7: 629-641.
Ansari S, Yamaoka Y. Helicobacter pylori virulence factors exploiting gastric colonization and its pathogenicity. Toxins (Basel) 2019; 11: 677.
Tuan VP, Yahara K, Dung HDQ et al. Genome-wide association study of gastric cancer- and duodenal ulcer-derived Helicobacter pylori strains reveals discriminatory genetic variations and novel oncoprotein candidates. Microb. Genom. 2021; 7.
Usui Y, Taniyama Y, Endo M et al. Helicobacter pylori, homologous-recombination genes, and gastric cancer. N. Engl. J. Med. 2023; 388: 1181-1190.